Prof Martin Eklund speaks to ecancer about prostate cancer screening using prostate-specific antigen, a multiplex blood-test, magnetic resonance imaging and targeted prostate biopsies within the STHLM3MRI trial.

Initially, he talks about the background of the study and discusses the fact that using the PSA test can result in the overdiagnosis of indolent cancer and that no country, with the exception of Lithuania, has a specific screening programme for prostate cancer.

Prof Eklund goes on to discuss the methodology and results of the study. He talks about the fact that this was a prospective, randomised, population-based trial during which men with a positive PSA or STHLM3 test result were assigned to a group undergoing a standardised biopsy or an MRI.

Finally, he discusses how the results from this study could impact the future of prostate cancer screening by reducing the number of indolent or clinically insignificant cancers that are detected. He also mentions upcoming publications regarding risk prediction and MRI utilisation, amongst others.